Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+Business Wire • 07/30/25
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced CancerBusiness Wire • 07/29/25
First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection TestBusiness Wire • 07/15/25
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025Business Wire • 07/14/25
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?Zacks Investment Research • 06/23/25
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer ScreeningBusiness Wire • 06/10/25
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast CancerBusiness Wire • 06/09/25
FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) TestBusiness Wire • 06/03/25
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based ScreeningBusiness Wire • 06/02/25
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast CancerBusiness Wire • 06/02/25
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment DecisionsBusiness Wire • 05/31/25
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid TestBusiness Wire • 05/27/25
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual MeetingBusiness Wire • 05/22/25
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid TumorsBusiness Wire • 05/21/25
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of CancerBusiness Wire • 05/20/25
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This YearBusiness Wire • 05/08/25
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue GuidanceBusiness Wire • 04/30/25
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor TypesBusiness Wire • 04/29/25